181 related articles for article (PubMed ID: 21737503)
41. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
42. Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614.
Koch WM; Ridge JA; Forastiere A; Manola J
Arch Otolaryngol Head Neck Surg; 2009 Sep; 135(9):851-8. PubMed ID: 19770416
[TBL] [Abstract][Full Text] [Related]
43. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
[TBL] [Abstract][Full Text] [Related]
44. Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients.
Schrader CH; Kolb M; Zaoui K; Flechtenmacher C; Grabe N; Weber KJ; Hielscher T; Plinkert PK; Hess J
Mol Cancer; 2015 May; 14():107. PubMed ID: 25990935
[TBL] [Abstract][Full Text] [Related]
45. Elevated expression of iASPP in head and neck squamous cell carcinoma and its clinical significance.
Liu Z; Zhang X; Huang D; Liu Y; Zhang X; Liu L; Li G; Dai Y; Tan H; Xiao J; Tian Y
Med Oncol; 2012 Dec; 29(5):3381-8. PubMed ID: 22815155
[TBL] [Abstract][Full Text] [Related]
46. CD44 variant isoforms in head and neck squamous cell carcinoma progression.
Wang SJ; Wong G; de Heer AM; Xia W; Bourguignon LY
Laryngoscope; 2009 Aug; 119(8):1518-30. PubMed ID: 19507218
[TBL] [Abstract][Full Text] [Related]
47. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
48. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
[TBL] [Abstract][Full Text] [Related]
49. Influence of allelic Variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab.
Muñoz C; Caballero M; Hakim S; Verger E; Grau JJ
Eur Arch Otorhinolaryngol; 2016 Aug; 273(8):2193-9. PubMed ID: 26245169
[TBL] [Abstract][Full Text] [Related]
50. BMP-2 expression correlates with local failure in head and neck squamous cell carcinoma.
Sand JP; Kokorina NA; Zakharkin SO; Lewis JS; Nussenbaum B
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):245-50. PubMed ID: 24247005
[TBL] [Abstract][Full Text] [Related]
51. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
[TBL] [Abstract][Full Text] [Related]
52. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
53. Nuclear NF-κB expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemoradiation therapy.
Balermpas P; Michel Y; Wagenblast J; Seitz O; Sipek F; Rödel F; Rödel C; Fokas E
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):785-90. PubMed ID: 23664323
[TBL] [Abstract][Full Text] [Related]
54. Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Harris BN; Pipkorn P; Nguyen KNB; Jackson RS; Rao S; Moore MG; Farwell DG; Bewley AF
JAMA Otolaryngol Head Neck Surg; 2019 Feb; 145(2):153-158. PubMed ID: 30570645
[TBL] [Abstract][Full Text] [Related]
55. Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients.
Farnebo L; Tiefenböck K; Ansell A; Thunell LK; Garvin S; Roberg K
Int J Cancer; 2013 Oct; 133(8):1994-2003. PubMed ID: 23564498
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of bone or cartilage invasion of locally advanced head and neck cancers.
Do L; Syed N; Puthawala A; Azawi S; Williams R; Vora N
Am J Clin Oncol; 2010 Dec; 33(6):591-4. PubMed ID: 20065851
[TBL] [Abstract][Full Text] [Related]
57. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
[TBL] [Abstract][Full Text] [Related]
58. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
59. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
60. Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome.
Erben PB; Brunner K; Hecht M; Haderlein M; Büttner-Herold M; Agaimy A; Fietkau R; Hartmann A; Distel LV
Int J Clin Exp Pathol; 2015; 8(12):15814-24. PubMed ID: 26884852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
